The investment has also increased the facility’s capabilities to support larger packaging campaigns through the addition of specialized secondary packaging capabilities for ULT products, as well as increasing its ability to handle biopharmaceuticals and advanced modalities, including mRNA-based vaccines, and cell and gene therapies.

“The Singapore site was the first Catalent clinical supply facility in the Asia-Pacific region, and now serves as a strategic supply hub, shipping clinical materials with high reliability and speed to over 20 countries,” said Tracey Clare, General Manager of APAC Operations for Catalent. “This year marks the site’s 25-year anniversary, and through the investments and expansions we have made over that time, it is well positioned to support the needs of modern Asia-Pacific and global clinical trials.”

Alongside sites in China and Japan, Catalent’s site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services including clinical supply management, comparator sourcing, Catalent’s FastChain^® demand-led supply solution, secondary packaging, storage, and global distribution, as well as clinical returns and destruction.